Skip to content

Study · Not a test of the peptide alone · 2023

1 result

pH/ROS-responsive propelled nanomotors for the active treatment of renal injury.

Tong F, Liu J, Luo L, Qiao L, Wu J, Wu G, Mei Q

Nanoscale6 Apr 2023Cited by 22 (Europe PMC)

PMID36942933 (opens in a new tab)DOI10.1039/d3nr00062a (opens in a new tab)PepBankPUB-36942933
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    A nanosystem carrying GYY4137 and TK-SS31 achieved effective drug distribution in the kidney, with pH-responsive H2S release and ROS-responsive SS31 release.

    In plain wordsA nanoparticle system with several active parts reached the kidney and released SS31 when reactive oxygen species were present.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableKidney drug distribution and ROS-responsive SS31 release
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Kidney and urinary

    Source sentences

    Summary
    The asymmetrical nanosystem achieved effective drug distribution in the kidney as well as pH-responsive hydrogen sulfide (H2S) release and ROS-responsive SS31 release

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.